UPDATE: Deutsche Bank Raises PT to $65 on Express Scripts

Deutsche Bank raises its price target on Buy-rated Express Scripts

to $65 from $59.50, reflecting several positive data points recently that may result in the FTC approval of the MHS transaction in the near term. Deutsche Bank notes, "We introduce our PF EPS for FY12E of $3.65 and FY13E of $4.65 and raise our PT from $59.50 to $65.00 (14x FY13E EPS). The combination of ESRX and MHS should allow the PF company to differentiate itself in several key ways. Strategically, the combined entities' focus on behavioral insights and health outcomes should allow it to increase patient adherence and bend the healthcare cost curve." ESRX closed at $53.65 a share on Friday.